Serum Autoantibodies against STIP1 as a Potential Biomarker in the Diagnosis of Esophageal Squamous Cell Carcinoma

Table 3

Results for measurement of the STIP1 autoantibodies in the diagnosis of ESCC.

	AUC	SEN	SPE	FPS	FNS	PPV	NPV	PLR	NLR
Training cohort
ESCC versus NC	0.682 (0.619–0.746)	41.9% (33.9%–50.3%)	90.1% (82.6%–94.7%)	9.9% (5.3%–17.4%)	58.1% (49.7%–66.1%)	84.9% (74.2%–91.9%)	53.8% (46.3%–61.0%)	4.23 (2.34–7.64)	0.64 (0.56–0.74)
Early-stage ESCC versus NC	0.684 (0.586–0.782)	35.7% (22.0%–52.0%)	90.1% (82.6%–94.7%)	9.9% (5.3%–17.4%)	64.3% (48.0%–78.0%)	57.7% (37.2%–76.0%)	78.7% (70.4%–85.3%)	3.60 (1.80%-7.20)	0.71 (0.57%-0.90)
Validation cohort
ESCC versus NC	0.710 (0.610–0.810)	40.0% (27.8%–53.5%)	92.5% (78.5%–98.0%)	7.5% (2.0%–21.5%)	60.0% (46.5%–72.2%)	88.9% (69.7%–97.1%)	50.7% (38.8%–62.5%)	5.33 (1.72–16.54)	0.65 (0.53–0.80)
Early-stage ESCC versus NC	0.756 (0.598–0.913)	38.5% (15.1%–67.7%)	92.5% (78.5%–98.0%)	7.5% (2.0%–21.5%)	61.5% (32.3%–84.9%)	62.5% (25.9%–89.8%)	82.2% (67.4%–91.5%)	5.13 (1.42–18.58)	0.67 (0.43–1.03)

All values are given with 95% CI in each group. ESCC: esophageal squamous cell carcinoma; NC: normal controls; AUC: area under the ROC curve; SEN: sensitivity; SPE: specificity; FPS: false positive rate; FNS: false negative rate; PPV: positive predictive value; NPV: negative predictive value; PLR: positive likelihood ratio; NLR: negative likelihood ratio.